Lineage Acquires NeuroAirmid Therapeutics
Benzinga Newsdesk 7 hours ago
NewsM&A
Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s DiseaseAcquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a
- Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s Disease
- Acquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a Clinical Trial Currently Enrolling Patients
- NeuroAirmid Shareholders Received $4.7 Million in Cash and Equity at Closing and are Eligible to Receive up to $5 Million on the First Anniversary of Closing and up to $48 Million in Success-based Milestones
- UCI Received a $12 Million Clinical Grant from the California Institute for Regenerative Medicine (CIRM) to support the REGEN4HD study